In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species.
Identifieur interne : 000108 ( Main/Exploration ); précédent : 000107; suivant : 000109In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species.
Auteurs : Patrick Schwarz [Allemagne] ; Eric Dannaoui [France]Source :
- Journal of fungi (Basel, Switzerland) [ 2309-608X ] ; 2020.
Abstract
The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or sirolimus) against 30 Aspergillus isolates belonging to the most common species responsible for invasive aspergillosis in humans (Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus) was evaluated in vitro by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing. The interpretation of the results was performed based on the fractional inhibitory concentration index. The combination of isavuconazole with tacrolimus, cyclosporin A, or sirolimus, was synergistic for 56, 20, or 10% of the isolates, respectively. Interestingly synergy of the combination of isavuconazole with tacrolimus was also achieved for the majority of azole-resistant isolates of A. fumigatus, and for all A. niger isolates with isavuconazole minimal inhibitory concentrations ≥ 8 µg/mL. Antagonistic interactions were never observed for any combination tested.
DOI: 10.3390/jof6030103
PubMed: 32650564
PubMed Central: PMC7560155
Affiliations:
- Allemagne, France
- District de Giessen, Hesse (Land), Île-de-France
- Créteil, Marbourg, Paris
- Université Paris-Est Créteil Val-de-Marne
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against <i>Aspergillus</i> Species.</title><author><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name><affiliation wicri:level="4"><nlm:affiliation>Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName><orgName type="university">Université Paris-Est Créteil Val-de-Marne</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32650564</idno><idno type="pmid">32650564</idno><idno type="doi">10.3390/jof6030103</idno><idno type="pmc">PMC7560155</idno><idno type="wicri:Area/Main/Corpus">000045</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000045</idno><idno type="wicri:Area/Main/Curation">000045</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000045</idno><idno type="wicri:Area/Main/Exploration">000045</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against <i>Aspergillus</i> Species.</title><author><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name><affiliation wicri:level="4"><nlm:affiliation>Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName><orgName type="university">Université Paris-Est Créteil Val-de-Marne</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Faculté de Médecine, Université de Paris, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Faculté de Médecine, Université de Paris, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of fungi (Basel, Switzerland)</title><idno type="eISSN">2309-608X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or sirolimus) against 30 <i>Aspergillus</i> isolates belonging to the most common species responsible for invasive aspergillosis in humans (<i>Aspergillus flavus</i>, <i>Aspergillus fumigatus</i>, <i>Aspergillus nidulans</i>, <i>Aspergillus niger</i>, and <i>Aspergillus terreus</i>) was evaluated in vitro by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing. The interpretation of the results was performed based on the fractional inhibitory concentration index. The combination of isavuconazole with tacrolimus, cyclosporin A, or sirolimus, was synergistic for 56, 20, or 10% of the isolates, respectively. Interestingly synergy of the combination of isavuconazole with tacrolimus was also achieved for the majority of azole-resistant isolates of <i>A. fumigatus</i>, and for all <i>A. niger</i> isolates with isavuconazole minimal inhibitory concentrations ≥ 8 µg/mL. Antagonistic interactions were never observed for any combination tested.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32650564</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2309-608X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of fungi (Basel, Switzerland)</Title><ISOAbbreviation>J Fungi (Basel)</ISOAbbreviation></Journal><ArticleTitle>In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against <i>Aspergillus</i> Species.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E103</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jof6030103</ELocationID><Abstract><AbstractText>The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or sirolimus) against 30 <i>Aspergillus</i> isolates belonging to the most common species responsible for invasive aspergillosis in humans (<i>Aspergillus flavus</i>, <i>Aspergillus fumigatus</i>, <i>Aspergillus nidulans</i>, <i>Aspergillus niger</i>, and <i>Aspergillus terreus</i>) was evaluated in vitro by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing. The interpretation of the results was performed based on the fractional inhibitory concentration index. The combination of isavuconazole with tacrolimus, cyclosporin A, or sirolimus, was synergistic for 56, 20, or 10% of the isolates, respectively. Interestingly synergy of the combination of isavuconazole with tacrolimus was also achieved for the majority of azole-resistant isolates of <i>A. fumigatus</i>, and for all <i>A. niger</i> isolates with isavuconazole minimal inhibitory concentrations ≥ 8 µg/mL. Antagonistic interactions were never observed for any combination tested.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0383-1865</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannaoui</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2817-3830</Identifier><AffiliationInfo><Affiliation>Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Médecine, Université de Paris, 75006 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Fungi (Basel)</MedlineTA><NlmUniqueID>101671827</NlmUniqueID><ISSNLinking>2309-608X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspergillus</Keyword><Keyword MajorTopicYN="N">EUCAST</Keyword><Keyword MajorTopicYN="N">antifungal combination</Keyword><Keyword MajorTopicYN="N">aspergillosis</Keyword><Keyword MajorTopicYN="N">immunosuppressor</Keyword><Keyword MajorTopicYN="N">in vitro</Keyword><Keyword MajorTopicYN="N">isavuconazole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32650564</ArticleId><ArticleId IdType="pii">jof6030103</ArticleId><ArticleId IdType="doi">10.3390/jof6030103</ArticleId><ArticleId IdType="pmc">PMC7560155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Rev Clin Oncol. 2014 Sep;11(9):536-47</Citation><ArticleIdList><ArticleId IdType="pubmed">24958183</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2016 Feb 1;62(3):362-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26486705</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2011 Sep;55(9):4465-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21690285</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):879-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17874329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2010 Apr;65(4):701-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20130026</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Aug 8;347(6):408-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12167683</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2015 Jun;21(6):1041-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25988348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2014 Nov;69(11):2979-83</Citation><ArticleIdList><ArticleId IdType="pubmed">25006238</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11600372</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagn Microbiol Infect Dis. 2020 May;97(1):115007</Citation><ArticleIdList><ArticleId IdType="pubmed">32081523</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2008 Feb;52(2):409-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18056277</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2013 Oct;9(10):e1003633</Citation><ArticleIdList><ArticleId IdType="pubmed">24204249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Mar 1;207(5):834-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23242544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Feb 20;387(10020):760-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26684607</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2013 Nov;57(11):5426-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23959309</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2001;40(8):573-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11523724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2007 Mar 1;195(5):756-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17262720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2008 Mar;61(3):577-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18194958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 Dec;9(12):789-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19926038</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3549-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19451295</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2004 Dec;48(12):4922-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15561883</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38</Citation><ArticleIdList><ArticleId IdType="pubmed">29544767</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 1999 Jun;10(6):1366-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10361877</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2013 Nov;57(11):5778-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24041890</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Apr 30;360(18):1870-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19403905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2001 Feb;39(2):478-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11158093</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2018 Oct 24;62(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">30181374</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2004 May;48(5):1664-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15105118</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2000 Mar;44(3):739-46</Citation><ArticleIdList><ArticleId IdType="pubmed">10681348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 2008 Mar;23(3):1048-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17956893</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Med Chem. 2016 Aug;8(12):1485-501</Citation><ArticleIdList><ArticleId IdType="pubmed">27463566</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10952582</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2000 Jan;44(1):143-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10602736</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1992 Apr;13(4):136-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1374612</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2008 Feb;52(2):735-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18070977</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2015 May 15;60(10):1505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25681376</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2003 Feb;51(2):313-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12562696</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1996;58(5):373-95</Citation><ArticleIdList><ArticleId IdType="pubmed">8594303</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015 May;70(5):1408-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25558076</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1983 Dec;24(6):921-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6660859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2012 Nov;65(5):453-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22898389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2019 Jul 1;74(7):1921-1927</Citation><ArticleIdList><ArticleId IdType="pubmed">30934052</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):7097-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26303797</ArticleId></ArticleIdList></Reference><Reference><Citation>Infection. 2009 Aug;37(4):313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19629387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1993 Nov 30;696:9-19</Citation><ArticleIdList><ArticleId IdType="pubmed">7509138</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2003 Mar;47(3):956-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12604527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 1998 Dec;42(6):747-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10052898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2019 Sep 19;10(1):4275</Citation><ArticleIdList><ArticleId IdType="pubmed">31537789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycoses. 2019 Sep;62(9):746-760</Citation><ArticleIdList><ArticleId IdType="pubmed">30830980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>France</li></country><region><li>District de Giessen</li><li>Hesse (Land)</li><li>Île-de-France</li></region><settlement><li>Créteil</li><li>Marbourg</li><li>Paris</li></settlement><orgName><li>Université Paris-Est Créteil Val-de-Marne</li></orgName></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name></region><name sortKey="Schwarz, Patrick" sort="Schwarz, Patrick" uniqKey="Schwarz P" first="Patrick" last="Schwarz">Patrick Schwarz</name></country><country name="France"><region name="Île-de-France"><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name></region><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name><name sortKey="Dannaoui, Eric" sort="Dannaoui, Eric" uniqKey="Dannaoui E" first="Eric" last="Dannaoui">Eric Dannaoui</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000108 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000108 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32650564
|texte= In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32650564" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |